XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level ...

Cory Ellspermann noted the net loss increased to $45.9 million from $42.1 million, reflecting sustained high operating losses ...

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Inmune Bio (INMB – Research Report) yesterday and set a price target of $16.00. Joel Beatty has given his Buy rating due to a combination ...

OmniScience and INmune Bio (INMB) announced a partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease, or AD, clinical trial using OmniScience’s product, Vivo, a ...

How Strong Is INmune Bio's Balance Sheet? We can see from the most recent balance sheet that INmune Bio had liabilities of US$3.23m falling due within a year, and liabilities of US$15.5m due beyond ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where INmune Bio, Inc. (NASDAQ:INMB) stands against ...

Inmune Bio’s latest earnings call painted a picture of steady operational progress offset by looming financial and execution risks. Management highlighted concrete steps toward regulatory filings and ...

Image source: The Motley Fool. INmune Bio (NASDAQ:INMB) delivered an update signaling concrete progress across its CORDStrom and XPro platforms, as well as disciplined financial management. Regulatory ...

As we reflect on 2025, I want to thank you for your continued support of INmune Bio. This past year marked an important period of execution, discipline, and focus as we advanced our mission to develop ...

Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug Development Boca Raton, FL, March 19, 2026 ...